Skip to main navigation
Skip to search
Skip to main content
Research Explorer The University of Manchester Home
Home
Profiles
Research units
Research output
Projects
Impacts
Activities
Press/Media
Prizes
Equipment
Datasets
Student theses
Search by expertise, name or affiliation
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer
Silke Gillessen Sommer
(Participant)
Division of Cancer Sciences (L5)
Impact
:
Health impacts
Narrative
The study investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radium-223.
Impact date
2016
Category of impact
Health impacts
Impact level
Benefit
Related content
Research output
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Research output
:
Contribution to journal
›
Article
›
peer-review
X